CatalystCorporate

Glaukos slips as insider selling overshadows positive trial data for eye therapy

Insider selling overshadows positive trial data, driving Glaukos shares lower.

What changed

Insider selling overshadows positive trial data, driving Glaukos shares lower.

Why it matters

Insider selling overshadows positive trial data, driving Glaukos shares lower. — impact context not separately stored; see What changed.

Sources